Kane Biotech Inc.

Equities

KNE

CA4838092084

Biotechnology & Medical Research

Market Closed - Toronto S.E. 11:37:58 2024-03-28 am EDT 5-day change 1st Jan Change
0.1 CAD 0.00% Intraday chart for Kane Biotech Inc. 0.00% +25.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Kane Biotech Inc., Q4 2023 Earnings Call, Mar 26, 2024
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kane Biotech Brief: Says otal revenue for the three months ended December 31, 2023 was $764,997 MT
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health MT
Kane Biotech Inc. Appoints Dr. Robert Huizinga as Director and Executive Chair CI
Transcript : Kane Biotech Inc. - Shareholder/Analyst Call
Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray CI
Kane Biotech Announces Correction to Press Release MT
Kane Biotech Inc. Announces Amendment to Its Credit Facility CI
Kane Biotech Gains 6% As Says To Sell Interest In STEM Animal Health MT
Kane Biotech To Sell Interest In STEM Animal Health MT
An undisclosed buyer signed a non-binding offer to acquire an unknown stake in STEM Animal Health Inc. from Kane Biotech Inc.. CI
An undisclosed buyer signed a non-binding offer to acquire an unknown entire stake in STEM Animal Health Inc. from Kane Biotech Inc.. CI
Transcript : Kane Biotech Inc., Q3 2023 Earnings Call, Nov 28, 2023
Kane Biotech Third-Quarter Loss Widens Despite Improved Revenue MT
Kane Biotech Brief: Loss for Q3 of 2023 was ($1,197,889), an increase of 41% compared to ($851,597) for the quarter ended September 30, 2022 MT
Kane Biotech Brief: Total revenue for three months ended September 30, 2023 was $717,852, an increase of 26% compared to $571,686 in three months ended September 30, 2022 MT
Kane Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Kane Biotech Inc. Appoints John Coleman to the Board of Directors CI
Kane Biotech Inc. and ProgenaCare Global Launch Newly Rebranded Revyve Antimicrobial Wound Care Fall Forum CI
Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall Forum MT
Kane Biotech Inc. to Exhibit At Symposium on Advanced Wound Care Fall Forum CI
Kane Biotech Inc. Announces Amendments to Its Credit Facility CI
Kane Biotech Inc. announced that it has received CAD 0.5 million in funding CI
Kane Biotech Second-Quarter Loss Widens Even as Revenue Rises 68% MT
Chart Kane Biotech Inc.
More charts
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Kane Biotech Inc. - Toronto S.E.
  4. News Kane Biotech Inc.
  5. Kane Biotech : First Quarter Loss Narrows Despite Sales Drop